GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Issuance of Stock

Eledon Pharmaceuticals (FRA:2TK) Issuance of Stock : €49.42 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Issuance of Stock?

Eledon Pharmaceuticals's Issuance of Stock for the three months ended in Sep. 2024 was €4.76 Mil.

Eledon Pharmaceuticals's Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was €49.42 Mil.


Eledon Pharmaceuticals Issuance of Stock Historical Data

The historical data trend for Eledon Pharmaceuticals's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Issuance of Stock Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.71 7.40 - - 30.28

Eledon Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 44.66 4.76

Eledon Pharmaceuticals Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €49.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eledon Pharmaceuticals Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals Headlines

No Headlines